Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 1,230,000 shares, a decline of 6.1% from the November 15th total of 1,310,000 shares. Approximately 3.8% of the company’s shares are short sold. Based on an average daily volume of 712,600 shares, the short-interest ratio is currently 1.7 days.

Werewolf Therapeutics Stock Up 6.0 %

Werewolf Therapeutics stock opened at $1.76 on Tuesday. The company has a 50 day moving average of $2.14 and a 200-day moving average of $2.34. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a twelve month low of $1.58 and a twelve month high of $8.19. The stock has a market capitalization of $78.43 million, a PE ratio of -1.08 and a beta of 0.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HOWL. Walleye Capital LLC grew its stake in shares of Werewolf Therapeutics by 10.7% during the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after acquiring an additional 10,528 shares in the last quarter. American Century Companies Inc. grew its holdings in Werewolf Therapeutics by 50.7% during the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after purchasing an additional 12,656 shares during the period. SG Americas Securities LLC acquired a new position in Werewolf Therapeutics during the third quarter worth approximately $29,000. Point72 DIFC Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $34,000. Finally, XTX Topco Ltd bought a new position in shares of Werewolf Therapeutics during the 3rd quarter worth approximately $45,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.